公开(公告)号：US10183992B2

公开(公告)日：2019-01-22

申请号：US15590514

申请日：2017-05-09

Applicant: IBC Pharmaceuticals, Inc.

Inventor： Chien-Hsing Chang ,  David M. Goldenberg ,  Edmund A. Rossi ,  Diane Rossi

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/18 ,  A61K38/21 ,  A61K47/42 ,  A61K39/395 ,  A61K45/06 ,  A61K38/19 ,  C07K16/40 ,  C07K16/32 ,  C07K16/44 ,  A61K9/00 ,  A61K38/17 ,  A61K38/45 ,  C07K14/47 ,  C07K16/46 ,  C07K14/00 ,  C12N9/12 ,  A61K47/60 ,  A61K47/64 ,  A61K39/00 ,  A61K38/00

Abstract: The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The cytotoxic immune response is enhanced by co-administration of interfon-based agents that comprise interferon-α, interferon-β, interferon-λ1, interferon-λ2 or interferon-λ3.

公开(公告)号：US09670286B2

公开(公告)日：2017-06-06

申请号：US15169903

申请日：2016-06-01

Applicant: IBC Pharmaceuticals, Inc.

Inventor： Chien-Hsing Chang ,  David M. Goldenberg ,  Edmund A. Rossi ,  Diane Rossi

IPC: C07K16/28 ,  C07K16/30 ,  A61K38/21 ,  A61K47/48 ,  A61K39/395 ,  A61K31/4745 ,  A61K45/06 ,  C07K16/44 ,  A61K39/00

CPC classification number: C07K16/30 ,  A61K31/4745 ,  A61K38/21 ,  A61K38/212 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/60 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6857 ,  A61K47/6859 ,  A61K47/6863 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/3007 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  A61K2300/00

Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.

公开(公告)号：US20170021017A1

公开(公告)日：2017-01-26

申请号：US15287329

申请日：2016-10-06

Applicant: IBC Pharmaceuticals, Inc.

Inventor： Chien-Hsing Chang ,  David M. Goldenberg ,  Edmund A. Rossi ,  Diane Rossi

IPC: A61K39/395 ,  C07K16/30 ,  A61K38/21 ,  C07K16/28 ,  A61K45/06 ,  A61K9/00

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61K38/21 ,  A61K38/212 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/44 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  A61K2300/00

Abstract: The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The leukocyte redirecting complexes have at least one binding site for a leukocyte antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3× anti-CD19 bispecific antibody, although antibodies against other leukocyte antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cells associated with cancer or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.

Abstract translation: 本发明涉及用于诱导对癌症或感染性疾病的免疫应答的两种或更多种试剂的组合。 试剂可以包括白细胞重定向复合物，抗体 - 药物偶联物，干扰素（优选干扰素-α）和/或检查点抑制剂抗体。 白细胞重定向复合物具有白细胞抗原的至少一个结合位点和患病细胞或病原体上的抗原的至少一个结合位点。 优选地，复合物是DNL TM复合物。 更优选地，复合物包含双特异性抗体（bsAb）。 最优选地，bsAb是抗CD3×抗CD19双特异性抗体，尽管可以使用针对其它白细胞抗原和/或疾病相关抗原的抗体。 该复合物能够靶向效应T细胞，NK细胞，单核细胞或嗜中性粒细胞，以诱导与癌症或感染性疾病相关的细胞的白细胞介导的细胞毒性。 通过共同给予干扰素，检查点抑制剂抗体和/或ADC来增强细胞毒性免疫应答。

公开(公告)号：US10308688B2

公开(公告)日：2019-06-04

申请号：US15064128

申请日：2016-03-08

Applicant: IBC Pharmaceuticals, Inc.

Inventor： Chien-Hsing Chang ,  David M. Goldenberg ,  Edmund A. Rossi ,  Diane Rossi

IPC: A61K39/395 ,  A61K9/19 ,  C07K16/30 ,  C07K16/28 ,  A61K38/21 ,  C07K14/00 ,  C07K16/18 ,  A61K47/42 ,  A61K45/06 ,  A61K38/19 ,  C07K16/40 ,  C07K16/32 ,  C07K16/44 ,  A61K9/00 ,  A61K38/17 ,  A61K38/45 ,  C07K14/47 ,  C07K16/46 ,  C12N9/12 ,  A61K47/60 ,  A61K47/64 ,  A61K39/00 ,  A61K38/00

Abstract: The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon-based agents that comprise interferon-α, interferon-β, interferon-λ1, interferon-λ2 or interferon-λ3.

公开(公告)号：US09382329B2

公开(公告)日：2016-07-05

申请号：US14600560

申请日：2015-01-20

Applicant: IBC Pharmaceuticals, Inc.

Inventor： Chien-Hsing Chang ,  David M. Goldenberg ,  Edmund A. Rossi ,  Diane Rossi

IPC: A61K38/21 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K47/48 ,  A61K31/4745 ,  A61K45/06 ,  C07K16/44 ,  A61K39/00

CPC classification number: C07K16/30 ,  A61K31/4745 ,  A61K38/21 ,  A61K38/212 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/60 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6857 ,  A61K47/6859 ,  A61K47/6863 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/3007 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  A61K2300/00

Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.

Abstract translation: 本发明涉及使用包含Trop-2（EGP-1）的至少一个结合位点和CD3的至少一个结合位点的双特异性抗体的组合物和方法。 双特异性抗体可用于诱导针对Trop-2表达肿瘤的免疫应答，例如食道癌，胰腺癌，肺癌，胃癌，结肠癌，直肠癌，膀胱癌，乳腺癌，卵巢癌，子宫癌，肾癌或前列腺癌。 所述方法可以包括单独施用双特异性抗体或与一种或多种治疗剂如抗体 - 药物偶联物，干扰素（优选干扰素-α）和/或检查点抑制剂抗体一起施用。 双特异性抗体能够靶向效应T细胞，NK细胞，单核细胞或嗜中性粒细胞以诱导白细胞介导的Trop-2 +癌细胞的细胞毒性。 通过共同给予干扰素，检查点抑制剂抗体和/或ADC来增强细胞毒性免疫应答。

公开(公告)号：US20140099254A1

公开(公告)日：2014-04-10

申请号：US14106737

申请日：2013-12-14

Applicant: IBC Pharmaceuticals, Inc.

Inventor： Chien-Hsing Chang ,  David M. Goldenberg ,  Edmund A. Rossi ,  Diane Rossi

IPC: A61K38/21 ,  A61K47/48 ,  A61K45/06 ,  A61K39/395

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61K38/21 ,  A61K38/212 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/44 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  A61K2300/00

Abstract: The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The leukocyte redirecting complexes have at least one binding site for a leukocyte antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other leukocyte antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cells associated with cancer or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.

Abstract translation: 本发明涉及用于诱导对癌症或感染性疾病的免疫应答的两种或更多种试剂的组合。 试剂可以包括白细胞重定向复合物，抗体 - 药物偶联物，干扰素（优选干扰素-α）和/或检查点抑制剂抗体。 白细胞重定向复合物具有白细胞抗原的至少一个结合位点和患病细胞或病原体上的抗原的至少一个结合位点。 优选地，复合物是DNL TM复合物。 更优选地，复合物包含双特异性抗体（bsAb）。 最优选地，bsAb是抗CD3×抗CD19双特异性抗体，尽管可以使用针对其它白细胞抗原和/或疾病相关抗原的抗体。 该复合物能够靶向效应T细胞，NK细胞，单核细胞或嗜中性粒细胞，以诱导与癌症或感染性疾病相关的细胞的白细胞介导的细胞毒性。 通过共同给予干扰素，检查点抑制剂抗体和/或ADC来增强细胞毒性免疫应答。

公开(公告)号：US10662252B2

公开(公告)日：2020-05-26

申请号：US15843252

申请日：2017-12-15

Applicant: IBC Pharmaceuticals, Inc.

Inventor： Chien-Hsing Chang ,  David M. Goldenberg ,  Edmund A. Rossi ,  Diane Rossi

IPC: C07K16/28 ,  A61K38/21 ,  A61K39/395 ,  A61K39/00 ,  C07K16/30 ,  A61K31/4745 ,  A61K45/06 ,  C07K16/44 ,  A61K47/60 ,  A61K47/68

Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.

公开(公告)号：US20180118846A1

公开(公告)日：2018-05-03

申请号：US15843252

申请日：2017-12-15

Applicant: IBC Pharmaceuticals, Inc.

Inventor： Chien-Hsing Chang ,  David M. Goldenberg ,  Edmund A. Rossi ,  Diane Rossi

IPC: C07K16/30 ,  C07K16/28 ,  A61K39/395 ,  A61K38/21

CPC classification number: C07K16/30 ,  A61K31/4745 ,  A61K38/21 ,  A61K38/212 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/60 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6857 ,  A61K47/6859 ,  A61K47/6863 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/3007 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  A61K2300/00

Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.

公开(公告)号：US09682143B2

公开(公告)日：2017-06-20

申请号：US14106737

申请日：2013-12-14

Applicant: IBC Pharmaceuticals, Inc.

Inventor： Chien-Hsing Chang ,  David M. Goldenberg ,  Edmund A. Rossi ,  Diane Rossi

IPC: A61K47/48 ,  C07K16/28 ,  C07K16/30 ,  A61K38/21 ,  A61K45/06 ,  A61K39/395 ,  C07K16/44 ,  A61K9/00 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61K38/21 ,  A61K38/212 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/44 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  A61K2300/00

Abstract: The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The leukocyte redirecting complexes have at least one binding site for a leukocyte antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other leukocyte antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cells associated with cancer or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.

公开(公告)号：US20170022274A1

公开(公告)日：2017-01-26

申请号：US15289357

申请日：2016-10-10

Applicant: IBC Pharmaceuticals, Inc.

Inventor： Chien-Hsing Chang ,  David M. Goldenberg ,  Edmund A. Rossi ,  Diane Rossi

IPC: C07K16/28 ,  A61K39/395 ,  A61K38/21 ,  A61K45/06 ,  A61K47/48 ,  C07K16/30 ,  A61K9/00

CPC classification number: C07K16/18 ,  A61K9/0019 ,  A61K38/00 ,  A61K38/1709 ,  A61K38/195 ,  A61K38/21 ,  A61K38/212 ,  A61K38/215 ,  A61K38/217 ,  A61K38/45 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/42 ,  A61K47/60 ,  A61K47/64 ,  A61K2039/505 ,  A61K2039/572 ,  C07K14/001 ,  C07K14/4702 ,  C07K16/2803 ,  C07K16/2806 ,  C07K16/2809 ,  C07K16/2812 ,  C07K16/2815 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/283 ,  C07K16/2833 ,  C07K16/2842 ,  C07K16/2845 ,  C07K16/2851 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2875 ,  C07K16/2878 ,  C07K16/2884 ,  C07K16/2887 ,  C07K16/289 ,  C07K16/2893 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3053 ,  C07K16/3076 ,  C07K16/3092 ,  C07K16/32 ,  C07K16/40 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/53 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/735 ,  C07K2319/74 ,  C07K2319/75 ,  C12N9/12 ,  C12Y207/11001 ,  C12Y207/11011 ,  Y02A50/466 ,  A61K2300/00

Abstract: The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon-based agents that comprise interferon-α, interferon-β, interferon-λ1, interferon-λ2 or interferon-λ3.

Abstract translation: 本发明涉及使用T细胞重定向复合物的组合物和方法，其中至少一个T细胞抗原的结合位点和病变细胞或病原体上的抗原的至少一个结合位点。 优选地，复合物是DNL TM复合物。 更优选地，复合物包含双特异性抗体（bsAb）。 最优选地，bsAb是抗CD3×抗CD19双特异性抗体，尽管可以使用针对其它T细胞抗原和/或疾病相关抗原的抗体。 该复合物能够靶向效应T细胞以诱导与疾病如癌症，自身免疫疾病或感染性疾病相关的细胞的T细胞介导的细胞毒性。 通过共同施用包含干扰素-α，干扰素-β，干扰素-λ1，干扰素-λ2或干扰素-λ3的基于干扰素的试剂来增强细胞毒性免疫应答。